Bevacizumab, an anti-VEGF monoclonal antibody, has shown preclinical efficacy in HHT-related AVMs by reducing vascular EC proliferation and increasing apoptosis (Walker et al, 2012). This evidence concerns the gene VEGFA and hereditary hemorrhagic telangiectasia.